Roche Q3 financials
This article was originally published in The Tan Sheet
Executive Summary
Swiss firm is setting aside approximately $808.8 mil. ($1=CHF 1.48) to settle ongoing vitamin price-fixing litigation, execs state during Oct. 10 conference call. "Over the last few weeks, we have made considerable progress in resolving major cases in the U.S. and elsewhere," company says. Vitamins & Fine Chemicals segment experienced 5% sales decline in Q3, but "sales volume grew significantly," Roche reports. Division's sale to DSM is "on track" to close in Q1 2003, firm says (1"The Tan Sheet" Sept. 9, 2002, p. 6)...